MTOR and prostate cancer: Meanwhile, reduction in 5-hmC by miR-29a/b activated prostate cancer-related key pathways such as mammalian target of rapamycin (mTOR) and AR, indicating significant oncogenic roles of miR-29 in prostate cancer progression [91].